

Industry Insight

INDIAN BULK DRUGS

April 2007

Cygnus

Business Consulting & Research

Knowledge Partner For Profitable Growth

4th & 5th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430303-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com

Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Cygnus Business Consulting & Research (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

SYNOPSIS

Indian bulk drugs market in 2006 was about US\$3.29 billion, witnessing a growth of 19% over 2005 and a compounded annual growth rate (CAGR) of 18.81% in the last six years. India ranks 4th in terms of volume, among the top 15 drug manufacturing countries worldwide. Indian companies have the distinction of developing cost-effective technologies for manufacturing bulk drugs and intermediates, conforming to global standards. India has over 80 US FDA approved plants, the second highest after the US.

Indian bulk drug market is fragmented with top 10 companies contributing 44% of the market and about 1,323 companies accounting for the balance 56%. Nearly 70% of the bulk drugs, manufactured are exported to more than 50 countries. Contract manufacturing in India in 2006 was USD658.6 million, registering a growth of 48% over previous year. Indian companies have filed 408 DMF's during 2006 out of a total 704. By 2010, Indian bulk drugs market is projected to grow to about US\$6.54 billion and contract manufacturing to USD1.5billion.

Indian Bulk Drug Industry Insight starts with an overview of the bulk drug industry with therapeutic segmentation and contract manufacturing. This report discusses in detail the nature of the Indian pharmaceutical market, market size, exports, imports and future outlook for the market. This report also analyses the critical success factors driving the industry as well as issues and challenges faced by the industry, such as competition from China and excess capacity. Besides, twenty major Indian companies have been profiled, covering aspects like products, key people, and financials for the last two years, key Strategies, DMF filings and future outlook for the company. Government regulations governing bulk drugs have been covered, along with details on production and pricing of bulk drugs. The report ends with future outlook for the industry for the next three years, covering market size, exports and imports. A detailed list of API manufacturers along with their contact details is given. Industry associations as well as key contacts are also provided at the end of the report.

The report will be useful to the pharmaceutical companies, exporters and importers – both in India and overseas, banks and investors to have an insight into Indian bulk drug industry. The educational institutes may also find it useful to have an in depth understanding of the industry. Government departments, Research bodies, industry experts, associations & consortia of the industry and consulting organizations will benefit by having an insight into the dynamics of the industry and also the issues and challenges faced by the industry.

The report has been prepared by referring to numerous published sources as well as interactions with the industry. All sources of data have been acknowledged.

Total number of pages : 105

Number of tables : 13

Number of charts : 17

CONTENTS

1. Executive Summary	8
2. Highlights	11
3. Market Overview	13
3.1. Introduction	13
3.1.1 Global Pharmaceutical Market	13
3.1.2 Leading Therapeutic Classes	14
3.1.3 Major Markets	16
3.2 Global Bulk Drugs Market	16
3.2.1 Market Size	16
3.2.2 Major Segments	18
3.2.3 Major Global Bulk Drugs Markets	18
3.2.4 Industry Structure	19
3.2.5 Industry Trends.....	21
4. Indian Bulk Drugs.....	23
4.1 Indian Pharmaceutical Market.....	23
4.1.1 Indian Bulk Drugs Market Size	25
4.1.2 Major Therapeutic Segments	25
4.1.3 Major Bulk Drugs.....	26
4.1.4 Industry Associations.....	30
4.1.4.1 Bulk Drug Manufacturers' Association (India)	30
4.1.4.2 Indian Drug Manufacturers Association (IDMA)	31
4.1.4.3 Organization of Pharmaceutical Producers in India (OPPI)	32
4.1.5 Industry Trends.....	33
4.1.5.1 Indian Bulk Drugs Exports	33
4.1.5.2 Indian Bulk Drugs Imports	33
5. Growth Drivers.....	34
5.1 High Growth of Generics / Patent expiries	34
5.2 New Drug Developments.....	35
5.3 Contract Manufacturing	36
5.4 Industry Regulations.....	38
5.4.1 Regulatory Bodies.....	38
5.4.2 Pharmaceutical Policy-2002.....	39
5.4.3 National pharmaceutical policy 2006.....	39

5.4.4 Pricing of Scheduled Bulk Drugs.....	40
5.4.5 Indian Patent law	40
5.4.6 Labelling System in India	41
5.4.7 Intellectual Property Rights (IPR)	42
5.4.8 Trade Related Aspects of Intellectual Property Rights (TRIPS).....	43
5.5 Overall Pharmaceutical Growth	44
5.6 Reduced Manufacturing Cost	45
5.7 Increasing Number of Small Players.....	45
6. Issues & Challenges	46
6.1 Increasing Competition.....	46
6.2 Coping with Changing Disease Profile	46
6.3 Over Capacity	47
6.4 Undifferentiated Capabilities.....	48
6.5 Varying regulatory requirements lead to additional costs	48
6.6 Threat from China	48
7. Major Players	51
7.1 Aurobindo Pharma	51
7.1.1 Business Profile.....	51
7.1.2 Financial Profile	52
7.1.3 Outlook	52
7.2 Ranbaxy Laboratories	53
7.2.1 Business Profile.....	53
7.2.2 Financial Profile	54
7.2.3 Outlook	54
7.3 Dr. Reddy's Laboratories	55
7.3.1 Business Profile.....	55
7.3.2 Financial Profile	56
7.3.3 Outlook	56
7.4 Lupin Ltd.....	57
7.4.1 Business Profile.....	57
7.4.2 Financial Profile	59
7.4.3 Outlook	59
7.5 Matrix Laboratories	60
7.5.1 Business Profile.....	60
7.5.2 Financial Profile	61

7.5.3 Outlook	62
7.6 Cipla Ltd.....	63
7.6.1 Business Profile.....	63
7.6.2 Financial Profile	64
7.6.3 Outlook	64
7.7 Orchid Chemicals and Pharmaceuticals Ltd.....	65
7.7.1 Business Profile.....	65
7.7.2 Financial Profile	66
7.7.3 Outlook	66
7.8 Divi's laboratories	67
7.8.1 Business profile	67
7.8.2 Financial Profile.....	68
7.8.3 Outlook	68
7.9 Sun Pharmaceutical Industries Ltd	69
7.9.1 Business Profile.....	69
7.9.2 Financial Profile	70
7.9.3 Outlook	71
7.10 IPCA Laboratories Ltd.	72
7.10.1 Business Profile.....	72
7.10.2 Financial Profile.....	73
7.10.3 Outlook	73
7.11 Wockhardt Limited.....	75
7.11.1 Business Profile.....	75
7.11.2 Financial Profile.....	76
7.11.3 Outlook	76
7.12 Cadila Healthcare Ltd.....	77
7.12.1 Business Profile.....	77
7.12.2 Financial Profile.....	78
7.12.3 Outlook	78
7.13 Alembic Ltd	79
7.13.1 Business Profile.....	79
7.13.2 Financial Profile.....	80
7.13.3 Outlook	80
7.14. Glaxo SmithKline Pharmaceuticals Ltd.	81
7.14.1 Business Profile.....	81
7.14.2 Financial Profile.....	82

7.14.3 Outlook	82
7.15 Glenmark Pharmaceuticals Ltd.....	83
7.15.1 Business Profile.....	83
7.15.2 Financial Profile	84
7.15.3 Outlook	84
7.16 Nicholas Piramal India Ltd. (NPIL)	85
7.16.1 Business Profile.....	85
7.16.2 Financial Profile	86
7.16.3 Outlook	86
7.17 Unichem Laboratories Ltd	87
7.17.1 Business Profile.....	87
7.17.2 Financial Profile	88
7.17.3 Outlook	88
7.18 Torrent Pharmaceuticals	89
7.18.1 Business Profile.....	89
7.18.2 Financial Profile	90
7.18.3 Outlook	90
7.19 Merck India Ltd.....	91
7.19.1 Business Profile.....	91
7.19.2 Financial Profile	92
7.19.3 Outlook	92
7.20 Atul Ltd	93
7.20.1 Business Profile.....	93
7.20.2 Financial Profile	93
7.20.3 Outlook	94
8. Critical Success Factors.....	95
8.1 Low- Cost Manufacturing Skills	95
8.2 Striking Strategic Alliances (Mergers & Acquisitions)	95
8.3 Growing Experience with cGMP Compliance.....	96
8.4 Complex Synthesis Capabilities.....	96
8.5 Identifying New Opportunities Holds the Key for Generic Manufacturers.....	96
9. Future Outlook	98
Annexure 1: List of Abbreviations.....	100
Annexure 2: List of Bulk Drugs Manufacturers in India.....	101

Annexure 3: List of Industry Organizations 105
Annexure 4: Bibilography..... 107

LIST OF CHARTS

- Chart 1: Global Pharmaceutical Market Value, 2002-2006
- Chart 2: Global Bulk Drugs Market Size, 2001-2006
- Chart 3: Market Share by Differentiation, 2000-2005
- Chart 4: Indian Pharmaceutical Market, 2002-2006
- Chart 5: Vision 2010: Glimpse of Indian Pharmaceutical Market Future
- Chart 6: Estimated Indian Bulk Drugs Market
- Chart 7: Major Therapeutic Segments, 2005-2006
- Chart 8: Estimated Indian Bulk Drugs Exports
- Chart 9: Estimated Indian Bulk Drugs Imports
- Chart 10: Value of Patent Expiries, 2006-2010
- Chart 11: R&D Spending by Major Pharmaceutical Companies in India, 2001-2006
- Chart 12: Global Contract Manufacturing Market, 2002-2011
- Chart 13: Estimated Indian Pharmaceutical Market
- Chart 14: DMF filings by China
- Chart 15: India & China DMF Filings
- Chart 16: Estimated Indian Bulk Drugs Market, 2006-2010E
- Chart 17: Estimated Indian Export and Import Trends, 2006-2010E

LIST OF TABLES

- Table 1: Leading Therapeutic Segments, 2006
- Table 2: Leading Brands, 2006
- Table 3: Major Markets, 2006
- Table 4: Global Bulk Drug Market
- Table 5: Global Bulk Drug Sales by Region, 2005
- Table 6: India overtakes Italy in Bulk Drug Production
- Table 7: Annual Production of Major Bulk Drugs
- Table 8: ANDA Filings by Indian Companies
- Table 9: DMF Filings by Indian Companies
- Table 10: India's Advantages for Contract Manufacturing
- Table 11: Key Contract Manufacturing Agreements
- Table 12: Comparison between India and China
- Table 13: Comparison of Top Level Companies: India/China